The effect of prednisolone on endometrial VGEF concentrations, Gene polymorphisms and pregnancy outcome in women with polycystic ovary syndrome: A retrospective cohort study
•Women who received prednisolone and those who did not received it, were compared, in terms of pregnancy results and the association complications.•Results inferred that the prednisolone increased VEGF significantly to normal levels along with other pregnancy-related and growth-related hormones.•Nor...
Gespeichert in:
Veröffentlicht in: | Journal of reproductive immunology 2020-02, Vol.137, p.103081-103081, Article 103081 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 103081 |
---|---|
container_issue | |
container_start_page | 103081 |
container_title | Journal of reproductive immunology |
container_volume | 137 |
creator | Bi, Huiling Aldakheel, Fahad M sawsan aloahd, Mustafa |
description | •Women who received prednisolone and those who did not received it, were compared, in terms of pregnancy results and the association complications.•Results inferred that the prednisolone increased VEGF significantly to normal levels along with other pregnancy-related and growth-related hormones.•Normal hormonal levels were achieved among patients who received prednisolone.•Genetic polymorphisms tend to exhibit different results based on population, ethnic groups etc.
PCOS (Polycystic Ovary Syndrome) occurs due to hyperandrogenism, excessive androgen, abnormal growth, steroidogenesis and seems to be associated with abnormal Vascular endothelial growth factor (VEGF) level in serum. The treatment is provided on the basis of body symptoms to mute the excess production of hormone. The study assessed the effect of prednisolone treatment on the concentration of VEGF, pregnancy outcomes and variants of VEGF SNPs. In the current retrospective study, the samples were collected from PCOS female patients who received prednisolone and those who did not received it, were compared along with control, in terms of pregnancy results and the association complications. The results inferred that the prednisolone made the concentration of VEGF significantly to normal levels along with other pregnancy-related and growth-related hormones. But the reduced normal limits were achieved only among few patients whereas no significant improvement found in the women who received prednisolone and control, in terms of pregnancy outcomes or complications. Further, there were no relations between the impact of treatment and the variants of VEGF SNPs. To conclude, there is no solid evidence found in the current study with regards to notable beneficial effect when the patients were treated with prednisolone, either in pregnancy outcomes or VEGF SNPs. The current study results should be considered only as a preliminary one since the genetic polymorphisms tend to exhibit different results based on population, ethnic groups etc. The results yielded may not be generalized due to differences in genetic background. |
doi_str_mv | 10.1016/j.jri.2020.103081 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2345507814</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165037820300024</els_id><sourcerecordid>2345507814</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-10f22db80417c6aae5e701d72beec8ea9171ca705fc30f19b345d6e22ca0900c3</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EotvCA3BBPnIgyzjZrBM4VVW7IFXqpeVqee0J61ViB9tZlIfqO3a2Wzhy8cjy9_8z45-xDwKWAsT6y365j25ZQnm8V9CIV2whGlkWcg3Va7Ygpi6gks0ZO09pDyAktOItO6tEKxu5ahfs8X6HHLsOTeah42NE610KffDIg-fobRgwR6d7_nNzfcNN8AZ9jjq74NNnvkECx9DPQ4jjzqUhce3t0eeX197MPEzZkAV3nv-hSqfLu2eFmVN2hoeDjjNPs7eR3r_ySx6pYUgjjeQOSB13IWae8mTnd-xNp_uE71_qBXu4ub6_-l7c3m1-XF3eFqaCOhcCurK02wZWQpq11lijBGFluUU0DepWSGG0hLojvhPttlrVdo1laTS0AKa6YJ9OvmMMvydMWQ0uGex77TFMSZUkqEE2YkWoOKGGZk4ROzVGN9BKSoA6pqT2ilJSx5TUKSXSfHyxn7YD2n-Kv7EQ8O0EIC15cBhVMg7p562L9C3KBvcf-yfir6dK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2345507814</pqid></control><display><type>article</type><title>The effect of prednisolone on endometrial VGEF concentrations, Gene polymorphisms and pregnancy outcome in women with polycystic ovary syndrome: A retrospective cohort study</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Bi, Huiling ; Aldakheel, Fahad M ; sawsan aloahd, Mustafa</creator><creatorcontrib>Bi, Huiling ; Aldakheel, Fahad M ; sawsan aloahd, Mustafa</creatorcontrib><description>•Women who received prednisolone and those who did not received it, were compared, in terms of pregnancy results and the association complications.•Results inferred that the prednisolone increased VEGF significantly to normal levels along with other pregnancy-related and growth-related hormones.•Normal hormonal levels were achieved among patients who received prednisolone.•Genetic polymorphisms tend to exhibit different results based on population, ethnic groups etc.
PCOS (Polycystic Ovary Syndrome) occurs due to hyperandrogenism, excessive androgen, abnormal growth, steroidogenesis and seems to be associated with abnormal Vascular endothelial growth factor (VEGF) level in serum. The treatment is provided on the basis of body symptoms to mute the excess production of hormone. The study assessed the effect of prednisolone treatment on the concentration of VEGF, pregnancy outcomes and variants of VEGF SNPs. In the current retrospective study, the samples were collected from PCOS female patients who received prednisolone and those who did not received it, were compared along with control, in terms of pregnancy results and the association complications. The results inferred that the prednisolone made the concentration of VEGF significantly to normal levels along with other pregnancy-related and growth-related hormones. But the reduced normal limits were achieved only among few patients whereas no significant improvement found in the women who received prednisolone and control, in terms of pregnancy outcomes or complications. Further, there were no relations between the impact of treatment and the variants of VEGF SNPs. To conclude, there is no solid evidence found in the current study with regards to notable beneficial effect when the patients were treated with prednisolone, either in pregnancy outcomes or VEGF SNPs. The current study results should be considered only as a preliminary one since the genetic polymorphisms tend to exhibit different results based on population, ethnic groups etc. The results yielded may not be generalized due to differences in genetic background.</description><identifier>ISSN: 0165-0378</identifier><identifier>EISSN: 1872-7603</identifier><identifier>DOI: 10.1016/j.jri.2020.103081</identifier><identifier>PMID: 31978749</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Adult ; Alleles ; Biopsy ; Case-Control Studies ; Endometrial cells ; Endometrium - blood supply ; Endometrium - drug effects ; Endometrium - pathology ; Endothelial growth factor (VEGF) ; Female ; Gene polymorphisms ; Genetic Predisposition to Disease ; Genetic variation ; Humans ; Polycystic ovary syndrome (PCOS) ; Polycystic Ovary Syndrome - blood ; Polycystic Ovary Syndrome - drug therapy ; Polycystic Ovary Syndrome - genetics ; Polycystic Ovary Syndrome - pathology ; Polymorphism, Single Nucleotide ; Prednisolone ; Prednisolone - administration & dosage ; Pregnancy ; Pregnancy Complications, Neoplastic - blood ; Pregnancy Complications, Neoplastic - drug therapy ; Pregnancy Complications, Neoplastic - genetics ; Pregnancy Complications, Neoplastic - pathology ; Pregnancy Outcome ; Retrospective Studies ; Serum VEGF levels ; Single nucleotide polymorphism ; Treatment Outcome ; Vascular ; Vascular Endothelial Growth Factor A - blood ; Vascular Endothelial Growth Factor A - genetics ; Vascular Endothelial Growth Factor A - metabolism ; Young Adult</subject><ispartof>Journal of reproductive immunology, 2020-02, Vol.137, p.103081-103081, Article 103081</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c305t-10f22db80417c6aae5e701d72beec8ea9171ca705fc30f19b345d6e22ca0900c3</cites><orcidid>0000-0001-7891-4011</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jri.2020.103081$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31978749$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bi, Huiling</creatorcontrib><creatorcontrib>Aldakheel, Fahad M</creatorcontrib><creatorcontrib>sawsan aloahd, Mustafa</creatorcontrib><title>The effect of prednisolone on endometrial VGEF concentrations, Gene polymorphisms and pregnancy outcome in women with polycystic ovary syndrome: A retrospective cohort study</title><title>Journal of reproductive immunology</title><addtitle>J Reprod Immunol</addtitle><description>•Women who received prednisolone and those who did not received it, were compared, in terms of pregnancy results and the association complications.•Results inferred that the prednisolone increased VEGF significantly to normal levels along with other pregnancy-related and growth-related hormones.•Normal hormonal levels were achieved among patients who received prednisolone.•Genetic polymorphisms tend to exhibit different results based on population, ethnic groups etc.
PCOS (Polycystic Ovary Syndrome) occurs due to hyperandrogenism, excessive androgen, abnormal growth, steroidogenesis and seems to be associated with abnormal Vascular endothelial growth factor (VEGF) level in serum. The treatment is provided on the basis of body symptoms to mute the excess production of hormone. The study assessed the effect of prednisolone treatment on the concentration of VEGF, pregnancy outcomes and variants of VEGF SNPs. In the current retrospective study, the samples were collected from PCOS female patients who received prednisolone and those who did not received it, were compared along with control, in terms of pregnancy results and the association complications. The results inferred that the prednisolone made the concentration of VEGF significantly to normal levels along with other pregnancy-related and growth-related hormones. But the reduced normal limits were achieved only among few patients whereas no significant improvement found in the women who received prednisolone and control, in terms of pregnancy outcomes or complications. Further, there were no relations between the impact of treatment and the variants of VEGF SNPs. To conclude, there is no solid evidence found in the current study with regards to notable beneficial effect when the patients were treated with prednisolone, either in pregnancy outcomes or VEGF SNPs. The current study results should be considered only as a preliminary one since the genetic polymorphisms tend to exhibit different results based on population, ethnic groups etc. The results yielded may not be generalized due to differences in genetic background.</description><subject>Adult</subject><subject>Alleles</subject><subject>Biopsy</subject><subject>Case-Control Studies</subject><subject>Endometrial cells</subject><subject>Endometrium - blood supply</subject><subject>Endometrium - drug effects</subject><subject>Endometrium - pathology</subject><subject>Endothelial growth factor (VEGF)</subject><subject>Female</subject><subject>Gene polymorphisms</subject><subject>Genetic Predisposition to Disease</subject><subject>Genetic variation</subject><subject>Humans</subject><subject>Polycystic ovary syndrome (PCOS)</subject><subject>Polycystic Ovary Syndrome - blood</subject><subject>Polycystic Ovary Syndrome - drug therapy</subject><subject>Polycystic Ovary Syndrome - genetics</subject><subject>Polycystic Ovary Syndrome - pathology</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Prednisolone</subject><subject>Prednisolone - administration & dosage</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Neoplastic - blood</subject><subject>Pregnancy Complications, Neoplastic - drug therapy</subject><subject>Pregnancy Complications, Neoplastic - genetics</subject><subject>Pregnancy Complications, Neoplastic - pathology</subject><subject>Pregnancy Outcome</subject><subject>Retrospective Studies</subject><subject>Serum VEGF levels</subject><subject>Single nucleotide polymorphism</subject><subject>Treatment Outcome</subject><subject>Vascular</subject><subject>Vascular Endothelial Growth Factor A - blood</subject><subject>Vascular Endothelial Growth Factor A - genetics</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><subject>Young Adult</subject><issn>0165-0378</issn><issn>1872-7603</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhi0EotvCA3BBPnIgyzjZrBM4VVW7IFXqpeVqee0J61ViB9tZlIfqO3a2Wzhy8cjy9_8z45-xDwKWAsT6y365j25ZQnm8V9CIV2whGlkWcg3Va7Ygpi6gks0ZO09pDyAktOItO6tEKxu5ahfs8X6HHLsOTeah42NE610KffDIg-fobRgwR6d7_nNzfcNN8AZ9jjq74NNnvkECx9DPQ4jjzqUhce3t0eeX197MPEzZkAV3nv-hSqfLu2eFmVN2hoeDjjNPs7eR3r_ySx6pYUgjjeQOSB13IWae8mTnd-xNp_uE71_qBXu4ub6_-l7c3m1-XF3eFqaCOhcCurK02wZWQpq11lijBGFluUU0DepWSGG0hLojvhPttlrVdo1laTS0AKa6YJ9OvmMMvydMWQ0uGex77TFMSZUkqEE2YkWoOKGGZk4ROzVGN9BKSoA6pqT2ilJSx5TUKSXSfHyxn7YD2n-Kv7EQ8O0EIC15cBhVMg7p562L9C3KBvcf-yfir6dK</recordid><startdate>202002</startdate><enddate>202002</enddate><creator>Bi, Huiling</creator><creator>Aldakheel, Fahad M</creator><creator>sawsan aloahd, Mustafa</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7891-4011</orcidid></search><sort><creationdate>202002</creationdate><title>The effect of prednisolone on endometrial VGEF concentrations, Gene polymorphisms and pregnancy outcome in women with polycystic ovary syndrome: A retrospective cohort study</title><author>Bi, Huiling ; Aldakheel, Fahad M ; sawsan aloahd, Mustafa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-10f22db80417c6aae5e701d72beec8ea9171ca705fc30f19b345d6e22ca0900c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Alleles</topic><topic>Biopsy</topic><topic>Case-Control Studies</topic><topic>Endometrial cells</topic><topic>Endometrium - blood supply</topic><topic>Endometrium - drug effects</topic><topic>Endometrium - pathology</topic><topic>Endothelial growth factor (VEGF)</topic><topic>Female</topic><topic>Gene polymorphisms</topic><topic>Genetic Predisposition to Disease</topic><topic>Genetic variation</topic><topic>Humans</topic><topic>Polycystic ovary syndrome (PCOS)</topic><topic>Polycystic Ovary Syndrome - blood</topic><topic>Polycystic Ovary Syndrome - drug therapy</topic><topic>Polycystic Ovary Syndrome - genetics</topic><topic>Polycystic Ovary Syndrome - pathology</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Prednisolone</topic><topic>Prednisolone - administration & dosage</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Neoplastic - blood</topic><topic>Pregnancy Complications, Neoplastic - drug therapy</topic><topic>Pregnancy Complications, Neoplastic - genetics</topic><topic>Pregnancy Complications, Neoplastic - pathology</topic><topic>Pregnancy Outcome</topic><topic>Retrospective Studies</topic><topic>Serum VEGF levels</topic><topic>Single nucleotide polymorphism</topic><topic>Treatment Outcome</topic><topic>Vascular</topic><topic>Vascular Endothelial Growth Factor A - blood</topic><topic>Vascular Endothelial Growth Factor A - genetics</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bi, Huiling</creatorcontrib><creatorcontrib>Aldakheel, Fahad M</creatorcontrib><creatorcontrib>sawsan aloahd, Mustafa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of reproductive immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bi, Huiling</au><au>Aldakheel, Fahad M</au><au>sawsan aloahd, Mustafa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of prednisolone on endometrial VGEF concentrations, Gene polymorphisms and pregnancy outcome in women with polycystic ovary syndrome: A retrospective cohort study</atitle><jtitle>Journal of reproductive immunology</jtitle><addtitle>J Reprod Immunol</addtitle><date>2020-02</date><risdate>2020</risdate><volume>137</volume><spage>103081</spage><epage>103081</epage><pages>103081-103081</pages><artnum>103081</artnum><issn>0165-0378</issn><eissn>1872-7603</eissn><abstract>•Women who received prednisolone and those who did not received it, were compared, in terms of pregnancy results and the association complications.•Results inferred that the prednisolone increased VEGF significantly to normal levels along with other pregnancy-related and growth-related hormones.•Normal hormonal levels were achieved among patients who received prednisolone.•Genetic polymorphisms tend to exhibit different results based on population, ethnic groups etc.
PCOS (Polycystic Ovary Syndrome) occurs due to hyperandrogenism, excessive androgen, abnormal growth, steroidogenesis and seems to be associated with abnormal Vascular endothelial growth factor (VEGF) level in serum. The treatment is provided on the basis of body symptoms to mute the excess production of hormone. The study assessed the effect of prednisolone treatment on the concentration of VEGF, pregnancy outcomes and variants of VEGF SNPs. In the current retrospective study, the samples were collected from PCOS female patients who received prednisolone and those who did not received it, were compared along with control, in terms of pregnancy results and the association complications. The results inferred that the prednisolone made the concentration of VEGF significantly to normal levels along with other pregnancy-related and growth-related hormones. But the reduced normal limits were achieved only among few patients whereas no significant improvement found in the women who received prednisolone and control, in terms of pregnancy outcomes or complications. Further, there were no relations between the impact of treatment and the variants of VEGF SNPs. To conclude, there is no solid evidence found in the current study with regards to notable beneficial effect when the patients were treated with prednisolone, either in pregnancy outcomes or VEGF SNPs. The current study results should be considered only as a preliminary one since the genetic polymorphisms tend to exhibit different results based on population, ethnic groups etc. The results yielded may not be generalized due to differences in genetic background.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>31978749</pmid><doi>10.1016/j.jri.2020.103081</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-7891-4011</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0165-0378 |
ispartof | Journal of reproductive immunology, 2020-02, Vol.137, p.103081-103081, Article 103081 |
issn | 0165-0378 1872-7603 |
language | eng |
recordid | cdi_proquest_miscellaneous_2345507814 |
source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE |
subjects | Adult Alleles Biopsy Case-Control Studies Endometrial cells Endometrium - blood supply Endometrium - drug effects Endometrium - pathology Endothelial growth factor (VEGF) Female Gene polymorphisms Genetic Predisposition to Disease Genetic variation Humans Polycystic ovary syndrome (PCOS) Polycystic Ovary Syndrome - blood Polycystic Ovary Syndrome - drug therapy Polycystic Ovary Syndrome - genetics Polycystic Ovary Syndrome - pathology Polymorphism, Single Nucleotide Prednisolone Prednisolone - administration & dosage Pregnancy Pregnancy Complications, Neoplastic - blood Pregnancy Complications, Neoplastic - drug therapy Pregnancy Complications, Neoplastic - genetics Pregnancy Complications, Neoplastic - pathology Pregnancy Outcome Retrospective Studies Serum VEGF levels Single nucleotide polymorphism Treatment Outcome Vascular Vascular Endothelial Growth Factor A - blood Vascular Endothelial Growth Factor A - genetics Vascular Endothelial Growth Factor A - metabolism Young Adult |
title | The effect of prednisolone on endometrial VGEF concentrations, Gene polymorphisms and pregnancy outcome in women with polycystic ovary syndrome: A retrospective cohort study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T12%3A09%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20prednisolone%20on%20endometrial%20VGEF%20concentrations,%20Gene%20polymorphisms%20and%20pregnancy%20outcome%20in%20women%20with%20polycystic%20ovary%20syndrome:%20A%20retrospective%20cohort%20study&rft.jtitle=Journal%20of%20reproductive%20immunology&rft.au=Bi,%20Huiling&rft.date=2020-02&rft.volume=137&rft.spage=103081&rft.epage=103081&rft.pages=103081-103081&rft.artnum=103081&rft.issn=0165-0378&rft.eissn=1872-7603&rft_id=info:doi/10.1016/j.jri.2020.103081&rft_dat=%3Cproquest_cross%3E2345507814%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2345507814&rft_id=info:pmid/31978749&rft_els_id=S0165037820300024&rfr_iscdi=true |